The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) withMyelofibrosis (MF) and Low Platelet (PLT) Count (50 × 109/L to < 100× 109/L) at Baseline

The Final Analysis of Expand

RETOUR